Cormedix (CRMD) reported $312M in revenue for fiscal 2025, +617.0% year on year. That ranks #2460 by revenue among 2853 SEC filers and #245 in Healthcare. Net income was $163M, a net margin of 52.3%. The fiscal 2025 balance sheet shows $826M in total assets and $145M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $312M | +617.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $276M | +584.5% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $150M | +$172M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $163M | +$181M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $175M | +$226M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.3M | +1,848.3% | FY20252025-12-31 |
| Total assetsAssets | $826M | +595.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $405M | +378.8% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $145M | +256.3% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $127M | $38.6M | Open → |
| Q2 20262026-06-30 | $102M | $26.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Cormedix Inc.
- Ticker
- CRMD
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001410098
Filings
- 10-QAug 13, 2026Open filing →
- 10-QMay 14, 2026Open filing →
- 10-KMar 5, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Fulgent GeneticsFLGT | $323M | −$60.5M |
| DocgoDCGO | $322M | −$196M |
| AngiodynamicsANGO | $320M | −$36.7M |
| CormedixCRMD | $312M | $163M |
| Procept BioroboticsPRCT | $308M | −$95,572 |
| BilliontooneBLLN | $305M | $7.5M |
| Skinhealth SystemsSKIN | $301M | −$9.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Cormedix — Key figures |url=https://companiesranked.com/en/company/cormedix |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Cormedix — Key figures. CompaniesRanked. https://companiesranked.com/en/company/cormedixBibTeX
@misc{companiesranked-en-company-cormedix-2026,
author = {{CompaniesRanked}},
title = {{Cormedix — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/cormedix}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001213900-26-023889 · March 5, 2026
{{cite web |title=Cormedix — Key figures — 10-K (0001213900-26-023889) |url=https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-05}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.